AMAG Pharma (AMAG) Posts Q4 EPS of $0.10 on Tax Reform Gain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Reports 2017 Financial Results and Company Update
February 27, 2018 7:00 AM EST2017 GAAP Revenue Increased 15% Year-over-Year
February 2018: Company Secures Two U.S. Food and Drug Administration (FDA) Approvals
Conference Call Scheduled for 8:00 a.m. ET Today
WALTHAM, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2017.
Total GAAP revenue for the full year of 2017 increased approximately 15% to $609.9 million, driven by increased sales growth across AMAG's portfolio, which includes Makena® (hydroxyprogesterone caproate injection), Feraheme® (ferumoxytol... More
